A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
- PMID: 37385276
- DOI: 10.1016/S0140-6736(23)01182-0
A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
Conflict of interest statement
SCB has received honoraria for presentations from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Roche, and Sanofi-Aventis, broadly related to GLP-1 receptor agonists for the treatment of diabetes, and travel expenses from Eli Lilly and Novo Nordisk. TM has received honoraria for presentations from Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, and Napp, broadly related to GLP-1 receptor agonists for the treatment of diabetes, and travel expenses from Napp. Eli Lilly is the sponsor of retatrutide and tirzepatide and Eli Lilly, Novo Nordisk, and Sanofi manufacture drugs based on GLP-1.
Comment on
-
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385280 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
